Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07232641 · ClinicalTrials.gov registry record
Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic
A clinical trial, sponsored by Boston University.
- Recruiting
- Registry status
- 185,810
- Enrollment target
NCT07232641: Recruiting study, sponsored by Boston University.
NCT07232641 is a clinical trial that is actively recruiting participants, run by Boston University. The registered enrollment target is 185,810 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07232641 is actively recruiting participants, sponsored by Boston University.
- RECRUITING
- Registry status
- 185,810 participants
- Enrollment target
Study Summary
"Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulations than medications for other substance use disorders, including medication for alcohol use disorder (MAUD), which created barriers to MOUD initiation and retention. These barriers were exacerbated by physical distancing and diminished clinic capacities during the COVID-19 pandemic. To prevent healthcare disruption and expand access to MOUD treatment during the public health emergency, federal and state authorities implemented several MOUD policy changes during the pandemic to reduce barriers to MOUD initiation and retention, which subsequently became permanent. This study is an evaluation of the impacts of these policies on treatment use, retention, and patient outcomes pre- and post-MOUD policy implementation.
Primary Outcome
Based on Current Procedural Terminology (CPT) codes abstracted from the Veterans Administration VA Corporate Data Warehouse (CDW)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185,810 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2029-09 |
What NCT07232641 shows while recruiting
NCT07232641 is an observational study that tracks outcomes without assigning an intervention. Its 185,810 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07232641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07232641 about?
NCT07232641 is a clinical study titled "Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic". "Gold-standard" medications for opioid use disorder (MOUD) treatment combines FDA-approved medications, primarily methadone and buprenorphine, with behavioral therapies to provide "whole-patient" treatment. Prior to the pandemic, methadone and buprenorphine were subject to greater federal regulation...
What is the current status of trial NCT07232641?
This trial is currently recruiting. The enrollment target is 185,810 participants. The study started on 2026-06-30. Estimated completion is 2029-09.
Who is sponsoring clinical trial NCT07232641?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI